RT Journal Article
SR Electronic
T1 Erythrocyte sedimentation rate as a new diagnostic biomarker for neuroacanthocytosis syndromes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20185041
DO 10.1101/2020.09.01.20185041
A1 Alexis Darras
A1 Kevin Peikert
A1 Antonia Rabe
A1 François Yaya
A1 Greta Simionato
A1 Thomas John
A1 Anil Kumar Dasanna
A1 Semen Buvalyy
A1 Jürgen Geisel
A1 Andreas Hermann
A1 Dmitry A. Fedosov
A1 Adrian Danek
A1 Christian Wagner
A1 Lars Kaestner
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.09.01.20185041.abstract
AB Chorea-acanthocytosis (ChAc) and McLeod syndrome (MLS) are the core diseases among the group of rare neurodegenerative disorders that comprise neuroacanthocytosis syndrome (NAS). Both ChAc and MLS patients present with an increased number of irregularly spiky erythrocytes, so-called acanthocytes. The detection of acanthocytes is often a crucial parameter in the diagnosis of NAS. However, this approach is error-prone and not very reliable, typically explaining the misdiagnosis of NAS patients. Based on the standard Westergren method, we show that compared with that in healthy controls, the erythrocyte sedimentation rate (ESR) with a two-hour read-out is significantly prolonged in ChAc and MLS with no overlap. Thus, the ESR is a clear, robust and easily obtained diagnostic marker. Mechanistically, by applying modern colloidal physics, we show that acanthocyte aggregation and plasma fibrinogen levels slow the sedimentation process. Apart from its diagnostic value, ESR may also be the first biomarker for monitoring treatments for NAS patients. Further studies are required to test whether the ESR may also detect other NASs. In addition to medical progress, this study is also a hallmark of the physical view of the erythrocyte sedimentation process by describing anticoagulated blood in stasis as a percolating gel, allowing the application of colloidal physics theory.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG) in the framework of the research unit FOR 2688 "Instabilities, Bifurcations and Migration in Pulsatile Flows", by the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860436 - EVIDENCE and by the Saarland University competitive funding (Forchungsausschuss). K.P. was supported by the Else Kroener Clinician Scientist Program (TU Dresden, Germany) and the Rostock Academy for Clinician Scientists (RACS, University of Rostock, Germany), A.H. is supported by the "Hermann und Lilly Schilling-Stiftung fuer medizinische Forschung im Stifterverband". F.Y., T.J. and C.W. acknowledge funding from French German University (DFH / UFA). We are indebted to the Advocacy for Neuroacanthocytosis Patients (www.naadvocacy.org) for financial support for chorea Western blotting. We also gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Juelich. We would like to thank Alexander Kihm and Dr. Hannes Glass for help in obtaining blood samples, their handling and transportation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this research was provided by the "Ethikkommission bei der Aerztekammer des Saarlandes" (Ethical Committee of the Saarland Medical Chamber).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost of the data generated and/or analyzed during this study are present in the paper or the Supplementary Figures. Intermediate technical results or newly design analyses software is available upon reasonable request to the corresponding authors.